SIRION Biotech offers full customisation services for gene therapy research and development (R&D). The company optimises adeno-associated virus (AAV) tissue specificity and immunogenic profiles.
AAVs are heavily utilised in modern gene therapy development. While standard AAV applications are suitable for pre-clinical target validation and proof-of-principle experiments, they can fall short during the big step into clinical application.
SIRION Biotech’s AAV optimisation platform enables you to address AAV limitations before you take that crucial step. All elements of your AAV strategy are considered and optimized with your project’s specific goals in mind.
The 3 tiers of successful AAV implementation:
- Transcriptional optimisation – Customised vector design and promotor choices to guarantee the optimal expression of your genetic strategy in the targeted tissues
- Transductional optimisation – AAV capsid mutations and surface variant constructions to optimize the tissue tropism
- Immunogenic optimisation – AAV capsid surface modulation to optimise or minimise the immunogenic profile of your AAV strategy
SIRION offers full project management capabilities for new AAV optimisations including a firm comprehension of all necessary patent frameworks and options to develop new intellectual properties within the optimisation project.